Genetic testing for BRCA ½ mutations for detecting breast and ovarian cancer
BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.
BRCAaccuTest™ and BRCAaccuTest™ PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the next generation sequencing (NGS) method, which analyzes genomic DNA derived from blood or FFPE tissue.
| BRCAaccuTest™ PLUS | ||
|---|---|---|
| Certification | CE-IVD | |
| Target disease | Breast/Ovarian cancer HBOC (Hereditary breast and ovarian cancer syndrome) |
|
| Target Enrichment method | Amplicon based method | |
| Quantity | 12 (6+6) test (1 test each for control DNA) |
24 test (1 test for control DNA) |
| Specimen | Blood, FFPE tissue, Tissue biopsy | |
| In-put DNA quantity | 10-30 ng | |
| Target gene | BRCA1 / BRCA2 | |
| Target region | 22.4 kb (all protein coding region, splicing regions, selected promoter, UTR, intron regions) | |
| amplicon | 160 (2 pools) | |
| Hands on time | >5 hrs | |
| Variants type | SNV, In, Del, Dup, CNV* | |
| NGS platform & reagent kit | illumina MiSeq, MiSeq Dx / MiSeq Reagent Nano, Micro kit, v2, 300cycles | |
| Samples throughput | Germline (11) / Somatic (5) | Germline (23) |
| Analysis solution | NGeneAnalySys™ (CE) | |
*CNV: RUO, Research Use Only
Supplier
NgeneBio
EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.
SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.
The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
